Panbela Therapeutics Inc
OTC:PBLA

Watchlist Manager
Panbela Therapeutics Inc Logo
Panbela Therapeutics Inc
OTC:PBLA
Watchlist
Price: 0.0112 USD -14.5%
Market Cap: 54.3k USD

Panbela Therapeutics Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Panbela Therapeutics Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Panbela Therapeutics Inc
OTC:PBLA
Net Income (Common)
-$35m
CAGR 3-Years
-67%
CAGR 5-Years
-42%
CAGR 10-Years
-30%
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Panbela Therapeutics Inc
Glance View

Market Cap
54.4k USD
Industry
Biotechnology

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 4 full-time employees. The company went IPO on 2014-07-29. The firm is focused on developing disruptive therapeutics for the treatment of patients with cancer. Its primary focus is on the treatment of patients with pancreatic cancer. Its lead product candidate, SBP-101, is a polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma, ovarian cancer and other tumors. The firm is conducting Phase Ia/Ib study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel.

PBLA Intrinsic Value
Not Available

See Also

What is Panbela Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-35m USD

Based on the financial report for Sep 30, 2024, Panbela Therapeutics Inc's Net Income (Common) amounts to -35m USD.

What is Panbela Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-30%

Over the last year, the Net Income (Common) growth was -49%. The average annual Net Income (Common) growth rates for Panbela Therapeutics Inc have been -67% over the past three years , -42% over the past five years , and -30% over the past ten years .

Back to Top